Cota reels in $40M in series C funding to advance its analytics program

20 dollar bills
Cota reeled in $40 million in series C funding to advance its analytics program. (StockSnap)

Cota, a healthcare data analytics company, raised $40 million in series C financing. The company said the funds will be used to advance its Cota Nodal Address (CNA) disease classification system.

The round of funding was led by IQVIA. EW Healthcare Partners was also a major participant. Joining in the funding round were Boston Millennia Partners, Horizon Blue Cross Blue Shield of New Jersey, Hackensack Meridian Health and Atoc Holdings.

The company said the money will be used to scale its product across providers, payers and life science companies. The company describes its CNA product as a “precision disease classification system” developed using comprehensive real-world data.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"With our CNA classification system and powerful analytics, we are confident that Cota will revolutionize both patient care and healthcare economics,” John Hervey, Cota’s chief executive, said in a statement. “The depth and richness of our real-world evidence set empowers life sciences companies to gain new insights into their compounds, accelerate market applications and support clinical trials.”

As the lead in the round, IQVIA received a seat on Cota's board of directors.


Suggested Articles

A toilet seat monitoring system aims to spot the signs of heart failure in the privacy of the home, with the goal of lowering hospital readmissions.

The FDA approved a heart implant from Impulse Dynamics for patients who aren’t able to use a pacemaker or standard therapies.

Sherlock Biosciences is launching with $35 million and a two-pronged approach to improving the current state of diagnostics.